ConductScience.org, home

Paper498151

Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II).

Belt RJ and 5 others. Cancer Treat Rep, 1979. Cited by 140 papers, by iCite.

Cite this record

ConductScience Library. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II). Papers, record 498151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/498151

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II).
PubMed
Journal
Cancer Treat Rep
PubMed
Year
1979
PubMed
Publication types
Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
140
iCite
Relative citation ratio, by iCite
6.83
iCite
Revised in PubMed
2013-11-21
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Belt RJR J
2Himmelstein KJK J
3Patton TFT F
4Bannister SJS J
5Sternson LAL A
6Repta AJA J

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CisplatinMajor topic
NeoplasmsMajor topic
Ascitic Fluid
Half-Life
Humans
Kidney
Mannitol
Protein Binding

Source PubMed

Download CSV of topics

Cited by33

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 140 citations.

PMIDTitleJournalYearIn PapersSource
38979778Impact of relative cisplatin dose to skeletal muscle mass on adverse events in patients with head and neck cancer undergoing chemoradiotherapy.Oncologist2024https://conductscience.org/library/papers/38979778PubMed
37448551Systemic Treatment for Gynecological Cancer Patients Undergoing Hemodialysis.Onco Targets Ther2023https://conductscience.org/library/papers/37448551PubMed
33572935The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry.Pharmaceuticals (Basel)2021https://conductscience.org/library/papers/33572935PubMed
32508921Limitations of Systemic Oncological Therapy in Breast Cancer Patients with Chronic Kidney Disease.J Oncol2020https://conductscience.org/library/papers/32508921PubMed
28856465Guidelines for treatment of renal injury during cancer chemotherapy 2016.Clin Exp Nephrol2018https://conductscience.org/library/papers/28856465PubMed
27586890
Advanced hepatocellular carcinoma with hepatic vein tumor thrombosis and renal dysfunction after hepatic arterial infusion chemotherapy effectively treated by liver resection with active veno-venous bypass: report of a case.
BMC Cancer2016https://conductscience.org/library/papers/27586890PubMed
19916578Cisplatin overdose: toxicities and management.Drug Saf2009https://conductscience.org/library/papers/19916578PubMed
12556954Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer.Br J Cancer2003https://conductscience.org/library/papers/12556954PubMed
11219485Anticancer drug-induced kidney disorders.Drug Saf2001https://conductscience.org/library/papers/11219485PubMed
10864227Clinical pharmacokinetics and administration of established platinum drugs.Drugs2000https://conductscience.org/library/papers/10864227PubMed
8573296Comparative adverse effect profiles of platinum drugs.Drug Saf1995https://conductscience.org/library/papers/8573296PubMed
7987972Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/7987972PubMed
7497604Long-term pharmacokinetic behavior of platinum after cisplatin administration.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7497604PubMed
7200547[Pharmacokinetic of platin in plasma and urine of man under 1-, 8-, and 24 h-infusion with cis-dichlorodiamine-platin (II) (cis-DDP) (author's transl)].Klin Wochenschr1982https://conductscience.org/library/papers/7200547PubMed
6883623Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer.Cancer Chemother Pharmacol1983https://conductscience.org/library/papers/6883623PubMed
6761344Phase II clinical trial of cis dichlorodiammine platinum (Cis DDP) in metastatic brain tumors.J Cancer Res Clin Oncol1982https://conductscience.org/library/papers/6761344PubMed
6189661Clinical pharmacokinetics of commonly used anticancer drugs.Clin Pharmacokinet1983https://conductscience.org/library/papers/6189661PubMed
4039488Comparison of the cytotoxic activities of chemotherapeutic drugs using a human bladder cancer cell line.Urol Res1985https://conductscience.org/library/papers/4039488PubMed
4038382Clinical pharmacology of high-dose cisplatin.Cancer Chemother Pharmacol1985https://conductscience.org/library/papers/4038382PubMed
3555940Pharmacokinetics of anticancer drugs in children.Clin Pharmacokinet1987https://conductscience.org/library/papers/3555940PubMed

See all 33 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/498151

GET https://conductscience.org/api/papers/v1/498151/cited_by?page=2